FTC Suffers Reversal On “Reverse Payments” Enforcement
This article was originally published in The Pink Sheet Daily
The Solicitor General says the Supreme Court should not hear the Commission's appeal of a case brought against Schering-Plough regarding a generic drug settlement.
You may also be interested in...
The Federal Trade Commission notes the threat of authorized generics, as well as its appeals court loss in the K-Dur case, as reasons for the jump in settlements.
Fox Chase Cancer Center’s Weeks concurs that umbrella agreements with pharma and biotech companies are becoming more common.
Tests are currently available to identify patient responders, but clinicians need guidance on how to adjust dosing for them, the HHS Secretary's Advisory Committee on Genetics, Health & Society agreed.